BRVE logo

BRVE Braveheart Bio, Inc.

NASDAQ · Biotechnology · Healthcare

$18.78
-0.71 (-3.64%)

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.

Market Cap: $1.33Bwww.braveheart.bio

Price

No data yet.

Social Signal Score

57
5d
—
30d
55
2 mentions
—
60d
55
2 mentions
—
90d
60
3 mentions
—
news: 3

Analyst Ratings

1 analyst
Buyconsensus
Strong Buy 0Buy 1Hold 0Sell 0Strong Sell 0
Avg price target$45.25+140.9%
Low $40Median $46.5High $48
Current Consensus

Revenue

$0.00
$0.00
Dec 31Sep 30

Analyst Estimates

FY2026
$-1.97
$-2.75–$-0.70
4 analysts
FY2027
$-1.51
$-1.66–$-1.35
4 analysts
FY2028
$-1.97
$-2.41–$-1.26
5 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Travis Murdoch
Sector
Healthcare
Industry
Biotechnology
Employees
49
Beta
0.00
Country
US
www.braveheart.bio